Home
Boundless Bio, Inc.

Boundless Bio, Inc. Market Share Analysis for May 2026

We at Boundless Bio are pioneers in understanding and treating the most intractable cancers. We have charted a new spatial map of the cancer genome within cancer cells and are harnessing our scientific founders’ discoveries about “extrachromosomal DNA,” or ecDNA, to drive a revolution in cancer therapeutics.

Industry: N/A

Domainboundlessbio.com

Year Founded2018

Employees51 - 200

Annual Revenue--

Boundless Bio, Inc.

Boundless Bio, Inc. (including company regionals)

boundlessbio.com

See more website traffic and engagement information

Total visits to Boundless Bio, Inc.'s top domains

Understand Boundless Bio, Inc. market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

boundlessbio.com4.1K

See more with Sales Intelligence

Avg. visit duration in Boundless Bio, Inc.'s top domains

Analyze Boundless Bio, Inc. engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

boundlessbio.com00:00:45

See more with Sales Intelligence

Avg. pageviews on Boundless Bio, Inc.'s top domains

See how Boundless Bio, Inc. keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

boundlessbio.com2.64

See more with Sales Intelligence

Boundless Bio, Inc. top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Boundless Bio, Inc.

These are the website technologies, by industry, used by Boundless Bio, Inc. top domains

Content Management System (3)

WordPress

Advertising (2)

DoubleClick

Conversion & Analytics (1)

Google Analytics

Customer Relationship Management (1)

Salesforce

More Technologies

6

See all

News & Signals from Boundless Bio, Inc.

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsBoundless Bio, Inc. merged with Serapha Bio on Jun 23rd '26.Boundless Bio and Serapha Bio to merge.

NewsBoundless Bio, Inc. attends event 2026 AACR Annual Meeting.Boundless Bio presents preclinical breast cancer data from its oral kinesin degrader program at 2026 AACR Annual Meeting.

NewsBoundless Bio, Inc. attended event American Association for Cancer Research (AACR) Annual Meeting 2026 on Apr 17th '26.SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) - Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced an upcoming poster presentation on their oral Kinesin degrader program at the American Association for Cancer Research (AACR) Annual Meeting 2026, which is being held April 17 - 22, in San Diego, CA.